New research shows patients commonly take lower doses of nintedanib, and the majority are also taking immunomodulatory drugs. Real-world data on usage of the tyrosine kinase inhibitor nintedanib (Ofev ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback